Dupilumab improved exacerbations and lung function in patients with COPD and T2 inflammation, regardless of baseline BODE index score.

Adults with COPD who used inhaled corticosteroids for more than 24 months faced higher risks for diabetes, osteoporosis, ...

The goal of complementary therapy is really is, to work in unison with conventional medicine and conventional interventions to really provide a holistic care for the patient. So a lot of patients ...

Significantly greater composite adverse outcome rates seen for long- versus short-term inhaled corticosteroid use for prevalent, inception cohorts.

MD: IL-33 inhibition with tozorakimab may offer clinical benefits in patients with COPD at high risk of exacerbations.

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for ...

This week Bobbi Conner talks with Dr. Kenneth Miller about the role of physical therapy in healthy aging. Dr. Miller is a ...

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...

Dupixent (dupilumab) is available in Japan in a 300 mg dose as a pre-filled syringe or pre-filled pen and is now available ...

About half of COPD patients continue to experience exacerbations despite being on triple inhaled therapy. Patients with COPD and elevated eosinophils have an increased risk of exacerbations and ...